x

Zoek een klinische studie of trial

* (*) verplicht veld

352 Resultaat/Resultaten

Sorteer op

Aanwerving proef = Aanwerving proef
; Lopend onderzoek = Lopend onderzoek
; Gefinancierd door een IRDiRC-lid =

Nationale klinische studie(s)

BELGIË

LIEGE
LIEGE

DUITSLAND

Baden-Württemberg
HEIDELBERG

DUITSLAND

Baden-Württemberg
HEIDELBERG

Aanwerving proef
Lopend onderzoek
BLAST: A double- blind, placebo controlled, randomized, multicenter, Phase II study to assess the efficacy of BL-8040 addition to consolidation therapy in AML patients - DE
Zentrum für Innere Medizin (Krehl-Klinik)
Abteilung Innere Medizin V - Hämatologie, Onkologie und Rheumatologie

DUITSLAND

Hessen
FRANKFURT AM MAIN

DUITSLAND

Nordrhein-Westfalen
DÜSSELDORF

DUITSLAND

Nordrhein-Westfalen
ESSEN

Aanwerving proef
Lopend onderzoek
AML-BFM 2012: Clinical trial for the treatment of acute myeloid leukemia in children and adolescents
Universitätsklinikum Essen
Klinik für Kinderheilkunde III - Abteilung für pädiatrische Hämatologie und Onkologie

DUITSLAND

Nordrhein-Westfalen
LEVERKUSEN

CLAVELA: A randomised phase III study of Elacytarabine versus investigator's choice in patients with late stage Acute Myeloid Leukaemia - DE - Completed
Klinikum Leverkusen
Medizinische Klinik 3 - Onkologie, Hämatologie, Palliativmedizin, Spezielle Schmerztherapie

DUITSLAND

Sachsen
DRESDEN

DUITSLAND

Sachsen
DRESDEN

Aanwerving proef
Lopend onderzoek
TUD-BRIDGE-046: Clofarabine salvage therapy in patients with relapsed or refractory Acute Myeloid Leukemia (Phase II Study)
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation

DUITSLAND

Sachsen
DRESDEN

Aanwerving proef
Lopend onderzoek
HINKL: Randomised controlled phase-2 trial to determine the efficacy of adoptive immunotherapy with haploidentical natural killer cells in high-risk acute myeloid leukemia - DE
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation

DUITSLAND

Sachsen
DRESDEN

Aanwerving proef
Lopend onderzoek
DELTA: A randomized placebo-controlled phase 2 study of decitabine/azacitidine with or without eltrombopag in AML patients = / > 65 years of age not eligible for intensive chemotherapy - DE
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation

DUITSLAND

Sachsen
DRESDEN

Aanwerving proef
Lopend onderzoek
ETAL3-ASAP: Evaluation of the Impact of Remission Induction Chemotherapy Prior to Allogeneic Stem Cell Transplantation in Relapsed and Poor-response Patients with AML (Phase III) - DE
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation

DUITSLAND

Sachsen
DRESDEN

SAMBA: Single Agent JNJ-56022473 in MDS and AML Patients Failing Hypomethylating Agent Based Therapy -DE-
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation

FRANKRIJK

AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR

FRANKRIJK

PROVENCE-ALPES-COTE D'AZUR
MARSEILLE

OOSTENRIJK

WIEN
WIEN

SEAMLESS: A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Hämatologie und Hämostaseologie

POLEN

Wroclaw
WROCLAW

CLAVELA: A Randomised Phase III Study of Elacytarabine vs. Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia - PL
Uniwersytet Medyczny im. Piastow Slaskich - Wroclaw Medical University
Klinika Hematologii, Nowotworow Krwi i Transplantacji Szpiku

SPANJE

Cataluña
GIRONA

SPANJE

Comunidad Valenciana
VALENCIA

SPANJE

Comunidad Valenciana
VALENCIA

SPANJE

Comunidad Valenciana
VALENCIA

SPANJE

Navarra
PAMPLONA

CLAVELA: A Randomised Phase III Study of Elacytarabine vs. Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia - ES (completed)
Complejo Hospitalario de Navarra - Hospital Virgen del Camino
Servicio de Hematología y Hemoterapia

VERENIGD KONINKRIJK

Greater London
LONDON

VERENIGD KONINKRIJK

Greater Manchester
ADDRESS: NOT PROVIDED - UK

VERENIGD KONINKRIJK

Greater Manchester
ADDRESS: NOT PROVIDED - UK

VERENIGD KONINKRIJK

Greater Manchester
ADDRESS: NOT PROVIDED - UK

VERENIGD KONINKRIJK

Nottinghamshire
NOTTINGHAM

VERENIGD KONINKRIJK

South Glamorgan
CARDIFF

AML 14: A Randomised Trial for Patients with Acute Myeloid Leukaemia or High Risk Myelodysplastic Syndrome Aged 60 or over (phase III) - UK
Cardiff University School of Medicine
Department of Medical Genetics, Haematology & Pathology

DENEMARKEN

Jylland
AARHUS

NOPHO-AML 2004 Study for Children With Acute Myeloid Leukemia (Phase III)
Aarhus Universitetshospital - Skejby
Department of Pediatrics

DUITSLAND

Baden-Württemberg
FREIBURG

DUITSLAND

Baden-Württemberg
HEIDELBERG

DUITSLAND

Baden-Württemberg
HEIDELBERG

Phase II open-label, AC220 monotherapy efficacy (ACE) study in patients with Acute Myeloid Leukemia (AML) with FLT3-ITD activating mutations - DE
Zentrum für Innere Medizin (Krehl-Klinik)
Abteilung Innere Medizin V - Hämatologie, Onkologie und Rheumatologie

DUITSLAND

Baden-Württemberg
TÜBINGEN

Aanwerving proef
Lopend onderzoek
CD3/CD19 Haplo (E410/2007): Multicenter phase II study of Haploidentical Hematopoietic Cell Transplantation with CD3/CD19 depleted Grafts after a reduced intensity conditioning regimen for adult Patients with Acute Leukemia
Department für Innere Medizin - Medizinische Universitätsklinik Tübingen
Innere Medizin II - Onkologie, Hämatologie, Klinische Immunologie, Rheumatologie und Pulmologie

DUITSLAND

Bayern
MÜNCHEN

Aanwerving proef
Lopend onderzoek
A Phase II Study Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes Failing Standard of Care Therapy -DE-
Klinikum rechts der Isar der Technischen Universität München
Klinik und Poliklinik für Innere Medizin III

DUITSLAND

Hessen
FRANKFURT AM MAIN

DUITSLAND

Niedersachsen
HANNOVER

AML-BFM 2004 : Multicenter therapy-optimization trial for the treatment of Acute Myeloid Leukemias in children and adolescents - DE
KPOH Geschäftsführung Hannover
Kompetenznetz Pädiatrische Onkologie und Hämatologie

DUITSLAND

Nordrhein-Westfalen
ESSEN

AML-BFM 2004 : Multicenter therapy-optimization trial for the treatment of Acute Myeloid Leukemias in children and adolescents - DE
Universitätsklinikum Essen
Klinik für Kinderheilkunde III - Abteilung für pädiatrische Hämatologie und Onkologie

DUITSLAND

Nordrhein-Westfalen
LEVERKUSEN

CP4055-205: A Phase II Study of Elacytarabine (CP-4055) plus Idarubicin as second course remission-induction therapy in patients with Acute Myeloid Leukaemia (AML) - DE
Klinikum Leverkusen
Medizinische Klinik 3 - Onkologie, Hämatologie, Palliativmedizin, Spezielle Schmerztherapie

DUITSLAND

Sachsen
DRESDEN

Gentuzumab ozogamicin before allogeneic stem cell transplantation in patients with relapsed CD33+ Acute Myeloid Leukemia (Phase I-II) - DE
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation

DUITSLAND

Sachsen
DRESDEN

TUD-LENAMA-022: Lenalidomide maintenance therapy in patients with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukaemia (AML) - Phase II study - DE
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation

DUITSLAND

Sachsen
DRESDEN

TUD-RELAZA-008: Treatment of the haematological relapse in patients with AML and MDS following allogenic Stem Cell Transplantation with 5-Azacitidine (Vidaza®) (Phase III) - DE
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation

DUITSLAND

Thüringen
JENA

Phase II study of Cladribine, high-dose Cytarabine and Idarubicin in patients with relapsed acute myeloid leukemia - DE
Universitätsklinikum Jena
Klinik für Innere Medizin II - Abteilung Hämatologie und Internistische Onkologie

FRANKRIJK

AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR

FRANKRIJK

AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR

FRANKRIJK

AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR

FRANKRIJK

AUVERGNE-RHONE-ALPES
LYON

CLARA-DNX : A Phase I/II study of clofarabine in combination with cytarabine and liposomal daunorubicin in children with relapsed/refractory pediatric AML
GH Est des HCL - Institut d'Hématologie et d'Oncologie Pédiatrique (IHOPe)
Service d'immuno-hématologie pédiatrique et de transplantation de moelle osseuse

FRANKRIJK

ILE-DE-FRANCE
LE CHESNAY

FRANKRIJK

ILE-DE-FRANCE
PARIS

Lopend onderzoek
TBF-Cord : Reduced Toxicity Conditioning Prior to Unrelated Cord Cell Transplantation for High Risk Myeloid Malignancies (Phase II)
CHU Paris Est - Hôpital Saint-Antoine
Service d'hématologie clinique et thérapie cellulaire

FRANKRIJK

ILE-DE-FRANCE
PARIS

Haploidentical NK-cell Infusion in Bad Prognosis AML Patients: Evaluation of Feasibility and Antitumoral Effect (Phase I-II) - FR
CHU Paris-GH La Pitié Salpêtrière-Charles Foix - Hôpital Pitié-Salpêtrière
Service d'Hématologie clinique

FRANKRIJK

ILE-DE-FRANCE
PARIS

Aanwerving proef
Lopend onderzoek
A phase II study of the efficacy and safety of lenalidomide combined to azacitidine in intermediate-2 or high risk MDS AND AML with del 5q (GFM-Aza-Rev-09)
CHU Paris-GH St-Louis Lariboisière F.Widal - Hôpital Saint-Louis
Groupe Francophone des Myélodysplasies (GFM)

FRANKRIJK

ILE-DE-FRANCE
PARIS

5-Azacitidine, Valproic Acid and ATRA in AML and High Risk MDS (Phase II) - Terminated -
CHU Paris-GH St-Louis Lariboisière F.Widal - Hôpital Saint-Louis
Service : Centre des Maladies du Sang

FRANKRIJK

ILE-DE-FRANCE
PARIS

Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) (Phase III)
CHU Paris-GH St-Louis Lariboisière F.Widal - Hôpital Saint-Louis
Service d'Hématologie seniors

FRANKRIJK

OCCITANIE
MONTPELLIER

FRANKRIJK

PROVENCE-ALPES-COTE D'AZUR
MARSEILLE

A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Acute Myeloid Leukemia - Terminated -
CLCC Institut Paoli Calmettes
Unité d'Evaluation Thérapeutique en Onco-Hématologie (ETHO)

FRANKRIJK

PROVENCE-ALPES-COTE D'AZUR
MARSEILLE

FRANKRIJK

PROVENCE-ALPES-COTE D'AZUR
MARSEILLE

FRANKRIJK

PROVENCE-ALPES-COTE D'AZUR
MARSEILLE

FRANKRIJK

PROVENCE-ALPES-COTE D'AZUR
MARSEILLE

ITALIË

FRIULI VENEZIA GIULIA
UDINE

ITALIË

LAZIO
ROMA

Risk-adapted, MRD-directed Therapy for Young Adults With Newly Diagnosed Acute Myeloid Leukemia
Azienda Ospedaliera Universitaria Policlinico di Tor Vergata
U.O.C. Ematologia

ITALIË

LAZIO
ROMA

Aanwerving proef
Lopend onderzoek
Study protocol for acute myeloid leukemia in children and adolescent
IRCCS Ospedale Pediatrico Bambino Gesù - SEDE GIANICOLO
U.O. di Onco-Ematologia

ITALIË

LAZIO
ROMA

ITALIË

MARCHE
PESARO

Phase II multicenter study of low dose Cytarabine + Tosedostat for previously untreated older patients with acute myeloid leukemia (AML)
A.O. Ospedali Riuniti Marche Nord - Presidio San Salvatore Centro
Ematologia e Centro Trapianti

NEDERLAND

Gelderland
NIJMEGEN

SPANJE

Cataluña
BADALONA

APL-R2007: Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) (Phase IV) (completed)
ICO Badalona - Hospital Germans Trias i Pujol
Servicio de Hematología Clínica

SPANJE

Cataluña
BARCELONA

SPANJE

Cataluña
BARCELONA

SPANJE

Comunidad Valenciana
VALENCIA

APL-R2007: Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) (Phase IV) (completed)
Hospital Universitario y Politécnico La Fe
Servicio de Hematología y Hemoterapia

SPANJE

Madrid
MADRID

SPANJE

Madrid
MADRID

APL-R2007: Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) (Phase IV) (completed)
Hospital Universitario 12 de Octubre
Servicio de Hematología y Hemoterapia

SPANJE

Madrid
MADRID

PETHEMA-LAM99: Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years (Phase IV) (terminated)
Hospital Universitario Ramón y Cajal
Servicio de Hematología y Hemoterapia

SPANJE

Navarra
PAMPLONA

VERENIGD KONINKRIJK

Greater London
LONDON

A Phase I Study of the Human Pharmacokinetics and Cardiac Safety of Elacytarabine - GB
St Bartholomew's Hospital, Barts and The London NHS Trust
Department of Medical Oncology

VERENIGD KONINKRIJK

South Glamorgan
CARDIFF

Lopend onderzoek
AML 16: A Programme of Treatment Development for Older Patients With Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome (PhaseII/III)
Cardiff University School of Medicine
Department of Medical Genetics, Haematology & Pathology

VERENIGD KONINKRIJK

South Glamorgan
CARDIFF

Aanwerving proef
Lopend onderzoek
AML 17: Randomised, controlled, open label, multi-arm trial looking at treatment for acute promyelocytic leukaemia (Phase III)
Cardiff University School of Medicine
Department of Medical Genetics, Haematology & Pathology

VERENIGD KONINKRIJK

South Glamorgan
CARDIFF

AML 15: Medical research council working parties on leukaemia in adults and children. Acute myeloid leukaemia trial 15 (Phase III)
Cardiff University School of Medicine
Department of Medical Genetics, Haematology & Pathology

VERENIGD KONINKRIJK

South Glamorgan
CARDIFF

AML-HR: Protocol for patients with high risk (resistant, refractory, relapsed or adverse cytogenetic) AML (Phase III)
Cardiff University School of Medicine
Department of Medical Genetics, Haematology & Pathology

VERENIGD KONINKRIJK

West Yorkshire
LEEDS

Multinationale klinische studie(s)

DUITSLAND

Berlin
ADDRESS: NOT PROVIDED - DE

VERENIGD KONINKRIJK

Greater Manchester
ADDRESS: NOT PROVIDED - UK

USA

New Jersey
RARITAN